Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

45
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
45
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

42
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
42
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

26
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
26
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

27
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
27
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

36
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
36
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced Mechanical Tactile Stimulation Under Space Microgravity Affects Synaptic Signaling and Contributes to Neuromuscular Aging in Caenorhabditis elegans.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Effects of an indole chemical, mitochonic acid 5, in a mouse model of mitochondrial disease onset.

Scientific reports·2026
Same author

An oral tyrosine challenge test for functional phenotyping of microbiota-derived phenyl sulfate production.

npj metabolic health and disease·2026
Same author

Universal transcriptomic hallmarks of mammalian ageing and mortality.

Nature·2026
Same author

RNase L Regulates Antiviral Responsiveness through Cleavage of XBP1 mRNA.

bioRxiv : the preprint server for biology·2026
Same author

High sensitivity chemiresistive biosensor prepared via enzyme-catalyzed redox and nanoparticle conduction network.

Microsystems & nanoengineering·2026

Related Experiment Video

Updated: Jul 24, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

223

[Therapy for CKD and DKD].

Takaaki Abe1,2,3

  • 1Division of Medical Science, Tohoku University Graduate School of Biomedical Engineering.

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|July 2, 2023
PubMed
Summary
This summary is machine-generated.

Phenyl sulfate (PS) is linked to diabetic kidney disease progression. Inhibiting gut bacteria enzyme tyrosine phenol-lyase (TPL) lowers PS levels and reduces albuminuria, offering a potential therapeutic strategy for DKD.

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

718
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.4K

Related Experiment Videos

Last Updated: Jul 24, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

223
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

718
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.4K

Area of Science:

  • Metabolomics
  • Microbiology
  • Nephrology

Context:

  • Diabetic kidney disease (DKD) is a leading cause of renal failure.
  • Type 2 diabetes significantly alters plasma metabolites, necessitating new management strategies.
  • Phenyl sulfate (PS) emerges as a key metabolite associated with diabetes progression.

Purpose:

  • To investigate the role of phenyl sulfate (PS) in diabetic kidney disease (DKD).
  • To explore the gut microbiota's contribution to PS production and its impact on DKD.
  • To evaluate the therapeutic potential of inhibiting gut bacterial tyrosine phenol-lyase (TPL) in DKD.

Summary:

  • Untargeted metabolome analysis revealed increased phenyl sulfate (PS) with diabetes progression.
  • PS administration in experimental models induced albuminuria and podocyte damage via mitochondrial dysfunction.
  • Clinical analysis confirmed PS levels correlate with albuminuria progression in DKD patients.
  • Gut bacteria synthesize phenol, metabolized to PS; inhibiting bacterial tyrosine phenol-lyase (TPL) reduced PS and albuminuria in diabetic mice.
  • TPL inhibition showed therapeutic advantages with lower resistance pressure.

Impact:

  • Phenyl sulfate (PS) is identified as a potential early diagnostic marker for DKD.
  • PS is a modifiable factor and a therapeutic target for DKD treatment.
  • Inhibiting microbiota-derived phenol offers a novel drug development avenue for DKD prevention.